This has to be a joke. They released an announcement to say that Halucenex, who CPH don't own and may never will, slightly tweaked the scope of participants in a clinical trial? And they even describe it as a "strategic decision"? Surely this breaches the new non-ramping rules for the ASX, no?
Talk about desperate times.
